NYSE:HAE
Haemonetics Corp.
Haemonetics Corp.'s revenue fell 2.0% in fiscal 2026 to $1.3B while operating margin fell to 11.7%. Free cash flow was $260.4M, 19.5% of revenue, and the diluted share count fell 6.7%.Summary generated from Haemonetics Corp.'s SEC filings. Latest annual report filed May 20, 2026.
Key statistics
Fiscal 2026 from SEC filings. MethodologyRevenue (FY26)$1.3B
Revenue growth−2.0%
Revenue, 5-yr CAGR+8.9%
Gross margin59.0%
Operating margin11.7%
Net margin7.3%
ROIC6.7%
Return on equity12.0%
Debt / equity1.56
Free cash flow$260.4M
FCF margin19.5%
Share count change−6.7%
Financials
| Item | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Revenue | 993 | 1,169 | 1,309 | 1,361 | 1,334 |
| Operating income | 81 | 156 | 165 | 222 | 157 |
| Net income | 43 | 115 | 118 | 168 | 97 |
| Free cash flow | 76 | 82 | 144 | 142 | 260 |
Recent filings
- 8-KRegulation FD disclosure
Oct 8, 2026 - 8-KRegulation FD disclosure
Aug 18, 2026 - 10-QQuarterly report for the period ended Jun 27, 2026
Aug 6, 2026 - 8-KResults of operations and financial condition
Aug 6, 2026 - 4Insider transaction report
Jul 28, 2026 - 4Insider transaction report
Jul 28, 2026 - 8-KDirector or officer change
Jul 28, 2026 - DEF 14AProxy statement
Jun 9, 2026